Welcome
Click here if you are not:
 

March 12, 2008 Archive

Certified for category 1 credit through March 12, 2010
Estimated time to complete: 1 hr

Instructions for participating in this CME activity:

ACCESS THE AUDIO PROGRAM IN 1 OF 3 WAYS:

On-Demand Webcast

MP3 Audio

Podcast

TO DOWNLOAD THE JOURNAL ARTICLE CLICK ON THE TITLE BELOW
TO DOWNLOAD THE SLIDES CLICK HERE

Learning Objectives | Faculty Disclosures | Evaluation Link

Article Title:

Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

(Click the name of the journal article to download the full text pdf)

Author:

Michael Heinrich, MD
Professor of Medicine and Cell and Developmental Biology
Hematology and Medical Oncology
Oregon Health and Science University
Portland, Oregon

Publication
Issue Date:

Journal Clinical Oncology
October 10, 2006

Moderator:

Jonathan C. Trent, MD, PhD
Assistant Professor of Medicine
Sarcoma Medical Oncology
The University of Texas MD
Anderson Cancer Center
Houston, Texas

Learning Objectives:

After taking part in this activity, participants should be able to:

  • Evaluate molecular markers of imatinib resistance in patients with advanced gastrointestinal stromal tumors (GISTs)
  • Discuss the clinical implications of the study's findings for future approaches to the growing challenge of imatinib resistance in patients with advanced GISTs
  • Review existing clinical trial data relating to molecular correlates of primary and secondary imatinib resistance in GISTs

Faculty Disclosures:

Jonathan C, Trent, MD, PhD, reports no such relationships.

Michael C. Heinrich, MD, has served as a consultant to Novartis Pharmaceuticals Corporation, and Pfizer Inc; has received honoraria from Novartis Pharmaceuticals Corporation; has received research support from Pfizer Inc and Novartis Pharmaceuticals Corporation; and has indicated ownership interests in Molecular MD.

The NCME staff reports no financial relationships to disclose.